CAR T-cell Therapy | Specialty

FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy

April 16th 2018

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

Dr. Younes Discusses the Future of CAR T-Cell Therapy

April 10th 2018

Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL

April 6th 2018

Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).

Novel Agents, CAR T Cells Reinvigorate ALL Landscape

April 5th 2018

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

Dr. Brentjens on Managing Patients After CAR T-Cell Therapy

April 4th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Perl on Potential CAR T-Cell Therapies in Hematologic Malignancies

March 28th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses potential chimeric antigen receptor (CAR) T-cells in hematologic malignancies.

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

March 27th 2018

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy

March 22nd 2018

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL

March 21st 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia.

T-Cell Fuel Source, Chemotherapy Exposure Reduce Potential to Develop CAR-T Therapy

March 15th 2018

Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.

Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant

March 13th 2018

Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.

Dr. Brentjens Discusses the Goal of Armored CAR T Cells

March 9th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Perl Highlights Latest CAR T-Cell Therapy Advances

March 5th 2018

Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.